Vascular Biogenics (VBLT) Stock: Gaining Big On Phase 2 Data


Vascular Biogenics Ltd (NASDAQ: VBLT)

Vascular Biogenics is having a great start to the trading session today, and for good reason. The company released overwhelmingly positive results from a recent Phase II clinical study. As a result, the stock started to climb dramatically, causing our partners at Trade Ideas to alert us of the gains. Currently (10:13), VBLT is trading at $5.25 per share after a gain of $0.75 per share or 16.67% thus far today.

VBLT Releases Positive Phase II Data

As mentioned above, Vascular Biogenics is having a strong morning in the market today as the result of positive data from a recent Phase II trial. The trial was designed around VB-111, an experimental treatment designed for patients with advanced, differentiated thyroid cancer.

According to the release, the primary endpoint was met. The data showed that 47% of patients in the therapeutic dose cohort achieved PFS-6, compared to 25% in the sub-therapeutic cohort. Both groups in the study met the primary endpoint of 25% PFS response at 6 months or 25% PFS-6.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be following VBLT incredibly closely. In particular, we’re interested in following the company’s ongoing work surrounding VB-111 as the treatment seems to be doing well in clinical studies. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Max Pixel]


Please enter your comment!
Please enter your name here